Faculty Opinions Recommendation of Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia

The document discusses a novel study where six premenopausal women with Female pattern hair loss (FPHL) were treated with bicalutamide mesotherapy. The patients, with a mean age of 35.7 years and diagnosed with Olsen Grade II or III alopecia, underwent three monthly sessions of 1ml bicalutamide 0.5% mesotherapy. Clinical images taken at baseline, after the third session, and 6 months post-first session were evaluated by two independent dermatologists. The study found an improvement in hair density after the third session, but the degree of alopecia remained unchanged. All patients reported improved hair density and seborrhea after 3 months of treatment, with an overall satisfaction score of 6.3. The study concluded that bicalutamide mesotherapy was well tolerated and welcomed by the patients.